Regeneron arrives at two consecutive medical conferences this month carrying something rarer than a single data readout: pivotal Phase 3 results for a disease so uncommon that palovarotene (Sohonos) only recently became its first approved therapy in the U.S. and Canada. The Week 56 primary analysis from the OPTIMA trial of garetosmab in fibrodysplasia ossificans progressiva headlines the ENDO schedule on June 13, and the weight of that presentation is amplified by the fact that the FDA has already accepted the garetosmab BLA for Priority Review. That sequence — pivotal data disclosed publicly while a Priority Review clock is running — puts every number from OPTIMA under immediate regulatory scrutiny.
FOP is a condition where muscles, tendons, and ligaments are progressively replaced by bone, leaving patients with shrinking mobility and no meaningful surgical remedy; a companion preclinical abstract at ENDO shows that blocking activin A prevents heterotopic bone from regrowing even after surgical resection in a mouse model, which directly answers the question of whether intervention can hold gains long-term. Garetosmab is an anti-activin A antibody, so the mechanistic story at ENDO is unusually coherent: the same target, three presentations, one regulatory moment. A qualitative interview poster from OPTIMA participants adds patient-experience evidence that payers and FDA reviewers increasingly treat as meaningful rather than decorative.
The ADA presentations carry a different kind of strategic weight. Three abstracts from the Phase 2 COURAGE trial examine trevogrumab — an anti-GDF8 antibody — added on top of semaglutide to preserve lean mass in people with obesity. The clinical concern is real: weight loss driven by GLP-1 receptor agonists includes a substantial lean-mass component, and at scale that translates into muscle loss across a large and growing patient population. Regeneron is positioning the trevogrumab-plus-semaglutide combination as a biologic answer to that problem, with a methodological poster on DXA imaging optimization in obese populations signaling that the team is also building the measurement infrastructure needed to make lean mass a credible primary endpoint in future trials.
Separately, two preclinical abstracts at ENDO introduce REGN24493, a TSH-receptor-blocking monoclonal antibody aimed at both Graves’ disease and thyroid eye disease — a single program targeting two conditions driven by the same underlying biology. Teprotumumab already holds FDA approval for thyroid eye disease via IGF-1 receptor inhibition, so the mechanistic differentiation Regeneron must establish for REGN24493 runs through the TSH receptor rather than the IGF-1 pathway. These are early mouse-model and in-vitro data, not yet human signals, but the program’s appearance at a major endocrinology meeting marks its first substantive public disclosure. The number to track from ENDO is the Week 56 heterotopic ossification volume change in OPTIMA — that single endpoint will define whether the garetosmab BLA review ends with an approval or a complete response letter.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
